Environmental MDL-2873 Open - Limited • District of South Carolina

AFFF Firefighting Foam Lawsuit (PFAS "Forever Chemicals")

This environmental contamination litigation involves PFAS chemicals from firefighting foam that have contaminated drinking water supplies across America. Tens of thousands of plaintiffs, including firefighters, military personnel, and people in communities near contaminated sites, are seeking compensation for cancer and other serious health conditions. On November 3, 2026, 3M agreed to pay up to $7.35 billion to resolve personal-injury claims against it. Claims against the other defendants continue.

Last Updated: November 2, 2026
24 min read
JPML Data Verified
16 sources cited

Key Takeaways

  • 3M agreed to pay up to $7.35 billion (about $5.8 billion in present value) on November 3, 2026 to resolve personal-injury claims of about 115,000 to 120,000 plaintiffs. The deal is opt-in and depends on sealed participation thresholds
  • November 13, 2026 is the deadline to identify eligible claimants to the court. Six injuries qualify: kidney, testicular, liver, and thyroid cancer, ulcerative colitis, and thyroid disease
  • Over 15,270 cases pending as of November 2026 with 100% growth
  • More than $11 billion in water-provider settlements reached with major manufacturers
  • PFAS chemicals classified as carcinogenic (Group 1) by IARC in November 2023
  • Firefighters, military personnel, and contaminated communities are primary plaintiffs
  • EPA set drinking water limit at 4 parts per trillion in 2024

November 2026 Updates Latest

Up to $7.35B
3M PI settlement (Nov 3)
Nov 13
Claimant ID deadline (CMO 39)
Stayed
PI cases vs 3M (CMO 40)
Jan 2028
Earliest main payment
Where it stands

On November 3, 2026, 3M signed an opt-in settlement to pay up to $7.35 billion over nine years (about $5.8 billion in present value) for the personal-injury claims of about 115,000 to 120,000 plaintiffs with one of six injuries. On November 4, Judge Gergel entered CMO 39, which requires every eligible claimant to be identified by November 13, 2026, and CMO 40, which stays personal-injury proceedings against 3M and sets strict record and expert-report deadlines for anyone who declines. The deal depends on sealed participation thresholds, and either side can walk away if they are not met. Claims against DuPont, Chemours, Corteva, and the other defendants are not settled. 15,270 cases are pending (19,846 total), up 6 from the October report. Full settlement breakdown below.

3M signs an up-to-$7.35 billion personal-injury settlement; the court enters CMO 39 and CMO 40 (Nov 3 and 4)

On November 3, 2026, 3M and the plaintiffs' Negotiating Plaintiffs' Counsel signed a Master Settlement Agreement, which 3M filed with the SEC that evening. It covers six injuries (kidney, testicular, liver, and thyroid cancer, ulcerative colitis, and thyroid disease) and exposure through drinking water or direct exposure. Every amount in the payment schedule is a maximum: $6.27 billion in six installments from 2028 to 2033, a $50 million initial payment, and up to $1.03 billion in reserve, threshold, and bonus payments. 3M can walk away if sealed participation thresholds are not met. On November 4, the court entered CMO 39 (identification deadline November 13) and CMO 40, which stays personal-injury proceedings against 3M and requires anyone who declines to produce records within 60 days and expert reports within 120 days, or face dismissal with prejudice. Read the full breakdown. See what CMO 39 and CMO 40 require.

3M's October 20 quarterly report: claims vetting "substantially complete," mediation continues, no trial date

In its Form 10-Q filed October 20, 2026, 3M said the special master appointed in June 2026 issued a report in September on defendants' first two sets of motions to dismiss plaintiffs who had not met the court's information requirements, recommending that most of the targeted claims be dismissed. According to 3M, the court largely adopted that report, and the vetting process is "now substantially complete, with tens of thousands of claims being dismissed without prejudice." 3M also said defendants' August 2026 motions to exclude expert testimony on liver and thyroid cancer remain pending, no new personal-injury trial date has been set, and court-ordered settlement talks on the personal-injury claims are "being actively facilitated by a court-appointed mediator." Two weeks later, those talks produced the November 3 settlement.

DuPont, Chemours and Corteva settle North Carolina's PFAS claims for $455 million (Sep 10, 2026)

On September 10, 2026, DuPont, Chemours and Corteva settled with North Carolina and 11 local entities for $455 million over 15 years (present value about $355 million). The deal resolves claims over the Fayetteville Works plant and the State's other PFAS claims, including from the use of AFFF. Of the total, $18 million is for non-Fayetteville claims, and no more than $14.4 million is for AFFF. It is not a personal-injury settlement.

The Group B bellwether schedule and the other defendants

CMO 38 (June 3, 2026) requires one action per personal-injury plaintiff. Under CMO 26O (July 30, 2026), proposals for selecting the Group B personal-injury bellwether cases (thyroid disease and ulcerative colitis) and for expert discovery are due November 20, 2026. Under CMO 33F (August 31, 2026), responses to Rule 702 expert motions on thyroid and liver cancer are due November 20, 2026, with replies due January 22, 2027. The new CMO 40 stay applies only to claims against 3M, and we had found no order changing the November 20 deadlines as of November 4. No other defendant has settled personal-injury claims. DuPont reported about 13,700 personal-injury cases in the MDL as of September 30, 2026 and said it continues talks with a mediator. More than $11 billion in water-provider settlements (including the DuPont/Chemours $1.185B public water suppliers fund) remain finally approved.

15,270
Pending Actions
$7.35B
3M PI Settlement (Maximum)
$11B+
Water-Provider Settlements
Group 1
IARC Cancer Rating (PFOA)

Key Facts (November 2026)

Pending Actions 15,270+ cases in federal MDL
3M Personal-Injury Settlement Up to $7.35 billion, 2026 to 2034 (present value about $5.8 billion); signed November 3, 2026
Eligible Injuries (3M deal) Kidney, testicular, liver, and thyroid cancer; ulcerative colitis; thyroid disease
Claimant ID Deadline November 13, 2026 (CMO 39)
Water-Provider Settlements More than $11 billion (3M, DuPont/Chemours)
3M Water-Supplier Settlement $10.3 billion over 13 years (2023)
IARC Classification Group 1: Carcinogenic to humans (PFOA)
EPA Drinking Water Limit 4 parts per trillion (PFOA/PFOS)
Presiding Judge Hon. Richard M. Gergel (D.S.C.)
MDL Created December 2018
Personal Injury Claims vs 3M Opt-in settlement; non-participants and new filers proceed under CMO 40
Personal Injury Claims vs Others Not settled; DuPont reports about 13,700 PI cases in the MDL
Settlement Signed November 3, 2026 · Court orders entered November 4, 2026

The 3M Personal-Injury Settlement

3M has agreed to pay up to $7.35 billion over nine years to resolve PFAS personal-injury claims in this MDL. The agreement, signed with the plaintiffs' Negotiating Plaintiffs' Counsel and filed with the SEC on November 3, 2026, is an opt-in settlement, not a class action: each eligible claimant decides whether to join. It is the first broad personal-injury resolution in MDL-2873. 3M admits no liability. Claims against DuPont, Chemours, Corteva, and the other defendants are not part of it.

Up to $7.35B
Maximum, 2026 to 2034
~$5.8B
Present value (3M)
115K to 120K
Eligible plaintiffs
Nov 13
Claimant ID deadline

Who is eligible

A person with a PFAS personal-injury claim asserting one of six "Eligible Injuries," whether or not the claim has been filed, served, or tolled, and in this MDL or another court.

Kidney cancer
Testicular cancer
Liver cancer
Thyroid cancer
Ulcerative colitis
Thyroid disease
  • •Exposure: through drinking water, from a public water system or a private well, or through direct exposure, such as handling AFFF.
  • •Not eligible: other health conditions, and property or business damage claims brought without a qualifying injury.
  • •Awards: scored on the diagnosis and the claimant's PFAS exposure. The scoring rules have not been made public, so there is no verified per-person amount.

How it works, step by step

  1. Nov 3, 2026
    Agreement signed

    3M and the plaintiffs’ Negotiating Plaintiffs’ Counsel sign the Master Settlement Agreement, filed with 3M’s Form 8-K.

  2. Nov 13, 2026
    Identification deadline (CMO 39)

    Lawyers must identify every eligible client, filed or not. People without a lawyer can identify themselves only if they already have a case in the MDL. Being identified does not commit anyone to join.

  3. 10 to 14 days later
    File and complete a fact sheet

    Identified claimants without a pending case must be filed in the MDL within 10 days, and anyone without a fact sheet must submit one within 14 days. Fact sheets submitted after November 3 bind claimants to the injuries and exposure they list.

  4. Final list
    The claimant list closes

    Lawyers cannot add clients who hired them after November 13. Anyone not on the final list can join only if both sides consent.

  5. Estimates
    Estimated award tables

    Each claimant gets an estimate that assumes only the main payment and 100% participation. It is not a guarantee.

  6. 98 days later
    Registration deadline

    Each claimant chooses: join, decline and stop litigating, or decline and keep litigating. The choice is binding and irrevocable.

  7. Participation count
    Walk-away window

    3M has 45 days after it receives the participation numbers to decide whether to terminate. Plaintiffs’ negotiating counsel has its own termination right.

  8. Jan 15, 2028+
    First main installment

    $1.045 billion, then five more through July 2033. Reserve payments run to April 2034.

Payment schedule (maximums)

From Exhibit 11 to the settlement agreement. All payments after the first $50 million depend on neither side exercising its termination rights. Total: $7.35B.

2026
$50M
2027
None
2028
$1.045B
2029
$1.204B
2030
$1.238B
2031
$1.163B
2032
$1.163B
2033
$1.147B
2034
$340M
Main settlement payment, $6.27B. Six installments of $1.045 billion, 2028 to 2033. 3M’s deck ties it to the first participation threshold.
Reserve Fund, $680M. Up to $680 million in six payments, 2029 to 2034, paid to participating claimants under a sealed formula. 3M owes none of it if CMO 40 stops being in effect.
Higher participation payments, $250M. Two payments of $125 million (2029 and 2030), owed only if the second and third participation thresholds are met.
Bonus payments, $100M. Two payments of $50 million (2031 and 2032) under sealed conditions. 3M’s deck calls them “payments contingent on future docket.”
Initial payment, $50M. Due within 30 days. Administrative costs are paid from it; what is left returns to 3M if either side terminates (MSA 11.1).

The participation test

The deal measures an overall participation rate and a separate rate for kidney and testicular cancer claimants with higher exposure. The required percentages are sealed. 3M has 45 days after it gets the numbers to decide whether to walk away, and plaintiffs' negotiating counsel has its own termination right. Joining is binding and irrevocable, and participants waive punitive damages.

If you don't join (CMO 40)

Claimants who decline, and anyone who files a new PFAS injury case against 3M in the MDL, must produce records and a sworn statute of limitations declaration within 60 days, including pharmacy records reaching back 10 years before diagnosis and proof they were at a home or other site served by contaminated water before diagnosis (private-well users need PFAS test results for the well). Within 120 days they must serve case-specific expert reports, including a fate and transport report tracing the PFAS into their water for drinking-water claims. Form expert reports are banned. Missing a deadline after a 30-day cure period means dismissal with prejudice. The order lasts at least 9 years. Full CMO 40 requirements.

What it does not cover

Personal-injury claims against DuPont, Chemours, Corteva, and other defendants; the new stay applies only to 3M. Water-provider claims, which were settled separately in 2023. Purchaser claims over firefighter turnout gear in MDL-3191. Conditions other than the six eligible injuries.

Still not public

  • • The participation percentages (Confidential Exhibit 12, sealing requested)
  • • The points matrix and the dollar value of a point
  • • Which companies are excluded from the release (Exhibit 9)
  • • Whether turnout-gear exposure scores as direct exposure
  • • Exact registration dates, which run from when estimates issue
  • • Whether the November 20 bellwether and expert deadlines change for other defendants

Sources: 3M Form 8-K and Master Settlement Agreement with Exhibit 11 (Nov. 3, 2026); 3M press release (Nov. 3, 2026) and investor presentation (Nov. 4, 2026); CMO 39 and CMO 40, MDL No. 2:18-mn-2873-RMG (D.S.C. Nov. 4, 2026); DuPont Form 10-Q (Nov. 3, 2026).

November 2023: PFOA Classified as "Carcinogenic to Humans"

The World Health Organization's International Agency for Research on Cancer (IARC) upgraded PFOA to Group 1 (carcinogenic to humans)—the highest classification—based on sufficient evidence for cancer in experimental animals and strong mechanistic evidence in humans. This is the same classification as asbestos and tobacco.

Source: IARC Monographs Volume 135, December 2023

Explosive Case Growth

One of the fastest-growing environmental MDLs. Case count has more than doubled in 2025, surging 100% as water contamination claims continue to be filed nationwide.

Jan 25
7,633
Feb 25
8,092
Mar 25
8,430
Apr 25
8,928
May 25
9,342
Jun 25
10,391
Jul 25
11,096
Aug 25
12,064
Sep 25
12,915
Oct 25
13,942
Nov 25
15,249
Dec 25
15,334
Jan 26
15,213
Feb 26
15,216
Mar 26
15,220
Apr 26
15,222
May 26
15,232
Jun 26
15,240
Jul 26
15,244
Aug 26
15,246
Sep 26
15,264
Oct 26
15,264
Nov 26
15,270

Source: JPML MDL Statistics Reports, January 2025-November 2026

1 Understanding PFAS: The "Forever Chemicals"

PFAS (per- and polyfluoroalkyl substances) are a group of manufactured chemicals that have been used since the 1940s. They're called "forever chemicals" because the carbon-fluorine bonds that make them so effective also make them nearly indestructible—they don't break down in the environment and can accumulate in your body over time.

AFFF (Aqueous Film-Forming Foam) is a firefighting foam specifically designed to extinguish fuel-based fires. According to the EPA, AFFFs containing PFAS have been used at airports, shipyards, military bases, firefighting training facilities, chemical plants, and refineries for decades.

Key PFAS Compounds in AFFF

PFOA Perfluorooctanoic acid – Group 1 Carcinogen
PFOS Perfluorooctane sulfonic acid – Widely used in AFFFs
PFHxS Perfluorohexane sulfonic acid
PFNA Perfluorononanoic acid

Source: CDC/ATSDR ToxFAQs for Perfluoroalkyls

2 Proven Health Effects of PFAS Exposure

Multiple government health agencies have confirmed that PFAS exposure causes serious health problems. Here's what the science shows:

Cancer Links (IARC/EPA/NCI Confirmed)

Kidney Cancer
PFOA linked (NCI)
Testicular Cancer
PFOA linked (NCI)
Prostate Cancer
Increased risk (EPA)

Sources: IARC Monographs Vol. 135; NCI Cancer Trends Progress Report; EPA PFAS Health Understanding

From EPA Studies

  • Decreased fertility in women
  • High blood pressure in pregnant women
  • Developmental delays in children
  • Hormone interference
  • Increased cholesterol/obesity risk

From CDC/ATSDR (July 2025)

  • Changes in liver enzymes
  • Lower antibody response to vaccines
  • Pregnancy-induced hypertension
  • Preeclampsia
  • Small decreases in birth weight

Immune System Damage (NTP Finding)

In 2016, the National Toxicology Program concluded that both PFOA and PFOS are "presumed to be an immune hazard to humans" based on high-level evidence from animal studies showing suppressed antibody response and moderate evidence from human studies.

Source: NTP Monograph on Immunotoxicity, September 2016

3 Who Has Been Exposed to PFAS?

Firefighters

IARC's 2023 evaluation of firefighting lists chemicals in firefighting foams, such as PFAS, among the exposures firefighters face, and classifies occupational exposure as a firefighter as carcinogenic to humans (Group 1). IARC also notes that people exposed to PFOA and PFOS at work can have high levels of exposure, mainly through inhalation.

  • • Airport firefighters
  • • Military firefighters
  • • Municipal firefighters
  • • Industrial firefighters

Military Personnel

AFFF was extensively used at military bases for fire training and aircraft emergencies. The CDC/ATSDR is currently conducting exposure assessments at communities near military installations.

  • • Air Force base personnel
  • • Naval base workers
  • • Army base firefighters
  • • Coast Guard personnel

Communities Near Contaminated Sites

PFAS have contaminated groundwater and drinking water supplies near locations where AFFF was used. The main exposure pathway for the general public is drinking contaminated water.

  • • Near military bases
  • • Near airports
  • • Near refineries
  • • Near training facilities

Industrial Workers

Workers at PFAS manufacturing facilities, those using PFAS in production, and waste management workers handling PFAS-contaminated materials face occupational exposure.

4 The Litigation: MDL-2873

Case Number
2:18-mn-02873-RMG
Presiding Judge
Hon. Richard M. Gergel
Court
U.S. District Court, District of South Carolina
MDL Created
December 2018

The Judicial Panel on Multidistrict Litigation consolidated AFFF cases in South Carolina because they share common questions about whether PFAS-containing firefighting foams contaminated groundwater and caused harm to people and communities.

Jan 2019
Court issued first Case Management Order establishing procedures
Feb 2019
Initial status conference to structure plaintiff and defendant leadership
Jun 2023
3M announces $10.3 billion settlement with water utilities
Nov 2023
IARC upgrades PFOA to Group 1 carcinogen classification
Apr 2024
EPA finalizes drinking water standards at 4 ppt for PFOA/PFOS
May 2025
3M agrees to pay New Jersey up to $450 million (final court approval August 2026)
Aug 2025
First personal-injury bellwether (kidney cancer, set for October 2025) vacated; court orders personal-injury claims to be filed and vetted
Nov 3, 2026
3M signs a personal-injury settlement of up to $7.35 billion
Nov 4, 2026
Court enters CMO 39 (Identification Order) and CMO 40 (stay as to 3M; rules for non-participants)
Nov 13, 2026
Deadline to identify all eligible claimants to the court

5 Major Settlements

Up to $7.35 Billion 3M Company, personal injury (2026)

On November 3, 2026, 3M signed an opt-in settlement to pay up to $7.35 billion from 2026 through 2034 (present value about $5.8 billion) for the personal-injury claims of about 115,000 to 120,000 plaintiffs with kidney, testicular, liver, or thyroid cancer, ulcerative colitis, or thyroid disease. It depends on sealed participation thresholds. See the breakdown above.

$10.3 Billion 3M Company, public water suppliers (2023)

3M agreed to pay $10.3 billion over 13 years to settle claims from public water systems. This is one of the largest environmental settlements in U.S. history and will help fund water treatment and remediation efforts.

$1.185 Billion DuPont/Chemours/Corteva (2023)

DuPont, Chemours, and Corteva agreed to pay $1.185 billion to settle water contamination claims from municipalities and water districts.

$455 Million DuPont/Chemours/Corteva with North Carolina (2026)

On September 10, 2026, DuPont, Chemours, and Corteva settled with North Carolina and 11 local entities for $455 million over 15 years (present value about $355 million). The deal resolves claims over the Fayetteville Works plant and the State's other PFAS claims, including from AFFF use. Only $18 million is for non-Fayetteville claims, and no more than $14.4 million is for AFFF. It is not a personal-injury settlement.

Important: The 2023 settlements resolved claims from water utilities, not individuals. Personal-injury claims against 3M are now addressed by the November 2026 opt-in settlement. Personal-injury claims against DuPont, Chemours, Corteva, and the other defendants have not been settled and continue.

6 EPA Drinking Water Standards (April 2024)

In April 2024, the EPA finalized the first-ever national drinking water standards for PFAS. These regulations set strict limits and require action by water systems. In May 2026, the EPA proposed changes to these standards (see below). The proposal is not final.

Maximum Contaminant Levels (MCLs)

Compound Goal (MCLG) Enforceable Limit
PFOA Zero 4.0 parts per trillion
PFOS Zero 4.0 parts per trillion
PFHxS 10 ppt 10 parts per trillion (proposed for rescission)
PFNA 10 ppt 10 parts per trillion (proposed for rescission)
GenX (HFPO-DA) 10 ppt 10 parts per trillion (proposed for rescission)

Source: EPA Safe Drinking Water Act PFAS Regulations, April 2024

May 2026 proposal (not final): On May 18, 2026, the EPA proposed keeping the 4.0 ppt limits for PFOA and PFOS, with an optional two extra years (to 2031) to comply, and rescinding the limits for PFHxS, PFNA, GenX, and the hazard index. These changes are proposed, not final.

By 2027

Public water systems must complete initial PFAS monitoring

By 2029

Treatment solutions must be implemented if levels exceed MCLs. The May 2026 proposal would allow an optional two extra years, to 2031, for PFOA and PFOS.

7 Do You Qualify for Compensation?

You may be eligible if you have documented PFAS exposure AND have been diagnosed with a qualifying condition. Timing now matters: under the 3M settlement, every eligible claimant must be identified to the court by November 13, 2026, and lawyers cannot add clients who hire them after that date.

Exposure Evidence Needed

  • Used AFFF as a firefighter or military personnel
  • Lived or worked near a military base, airport, or industrial facility using AFFF
  • Drank water from a contaminated municipal supply or private well
  • Blood tests showing elevated PFAS levels

Eligible Injuries Under the 3M Settlement

• Kidney cancer
• Testicular cancer
• Liver cancer
• Thyroid cancer
• Ulcerative colitis
• Thyroid disease

These are the only six "Eligible Injuries" in the agreement. Other conditions associated with PFAS in health studies, such as high cholesterol or pregnancy-related conditions, are not eligible injuries under the 3M deal.

Medical Testing: In July 2022, the National Academies of Sciences recommended that doctors offer PFAS blood testing to patients with likely elevated exposure history. Ask your doctor about testing if you believe you've been exposed.

8 Frequently Asked Questions

Is there a 3M AFFF personal injury settlement?
Yes. On November 3, 2026, 3M signed an opt-in settlement to pay up to $7.35 billion from 2026 through 2034 (present value about $5.8 billion) for the personal-injury claims of about 115,000 to 120,000 plaintiffs with kidney, testicular, liver, or thyroid cancer, ulcerative colitis, or thyroid disease. It is not final: it depends on sealed participation thresholds, and either side can walk away if they are not met. Eligible claimants must be identified to the court by November 13, 2026. No per-person amounts have been published. Full breakdown.
What happens if I don't join the 3M settlement?
Under Case Management Order 40 (November 4, 2026), claimants who decline and keep suing 3M, and anyone who files a new PFAS injury case against 3M in the MDL, must produce their records within 60 days, including complete medical records, pharmacy records reaching back 10 years before diagnosis, and proof they were at a home, facility, or other site served by a contaminated water source before diagnosis, along with a sworn statute of limitations declaration. Within 120 days they must serve expert reports on general and specific causation, and drinking-water claims also need an expert report tracing the probable source of the PFAS into the plaintiff's water. Form or template expert reports are not allowed. After a 30-day cure period, the court will dismiss non-compliant claims with prejudice absent good cause. Other personal-injury proceedings against 3M in the MDL are stayed. See the full CMO 39 and CMO 40 requirements.
How do I know if my water is contaminated with PFAS?
Contact your local water utility and ask for PFAS test results. Under the new EPA regulations, all public water systems must complete PFAS testing by 2027 and report results. Private well owners can have water tested through certified laboratories. You can also check the EPA's PFAS contamination maps or EWG's Tap Water Database for known contamination sites.
Do I need a cancer diagnosis to file a claim?
No, but you need one of the qualifying conditions. The 3M personal-injury settlement covers six: kidney, testicular, liver, and thyroid cancer, plus two non-cancer conditions, ulcerative colitis and thyroid disease. Property or business damage alone does not qualify under that settlement. Water utilities resolved their contamination claims through separate settlements.
I'm a firefighter. Am I eligible?
Firefighters who used AFFF during training or fire suppression are among the most affected groups, and the 3M settlement scores "direct" exposure, such as handling AFFF, alongside drinking-water exposure. To take part, a firefighter needs one of the six eligible injuries and must be on the identification list due November 13, 2026. Firefighters who keep suing 3M under CMO 40 must produce employment or military records, AFFF training records, and records of the turnout gear they used, and if all of their AFFF exposure came after 2002, the documents they have showing that 3M's brand of AFFF was used. IARC classifies occupational exposure as a firefighter as carcinogenic to humans (Group 1) and lists chemicals in firefighting foams, such as PFAS, among the exposures firefighters face.
What does the IARC Group 1 classification mean?
Group 1 is IARC's highest classification, meaning there is sufficient evidence that PFOA causes cancer in humans. This is the same classification given to asbestos, tobacco smoke, and benzene. The 2023 upgrade from Group 2B significantly strengthens the scientific basis for cancer claims.
Did the $10.3 billion settlement resolve all claims?
No. The 2023 settlement resolved claims from public water systems for remediation costs. Personal-injury claims are separate. Those against 3M are now addressed by 3M's November 2026 opt-in settlement of up to $7.35 billion, and those against DuPont, Chemours, Corteva, and other defendants have not been settled.
Can I get a blood test for PFAS?
Yes. The National Academies of Sciences has recommended that clinicians offer PFAS blood testing to patients with likely elevated exposure history. Talk to your doctor about testing, particularly if you're a firefighter, military veteran, or have lived near a known contamination site. Some states have programs providing free testing to affected communities.

Sources & References

16 official sources cited

• EPA: "Our Current Understanding of the Human Health and Environmental Risks of PFAS"

• CDC/ATSDR: "PFAS and Your Health" (Updated July 2025)

• IARC Monographs Volume 135 (December 2023)

• IARC Monographs Volume 132: Occupational Exposure as a Firefighter (2023)

• National Cancer Institute: Cancer Trends Progress Report

• National Toxicology Program: Monograph on Immunotoxicity (2016)

• EPA Safe Drinking Water Act PFAS Regulations (April 2024)

• EPA: Proposed changes to the PFAS drinking water regulation (May 18, 2026)

• U.S. District Court (D.S.C.), MDL-2873 case management orders: CMO 38 (June 3, 2026), CMO 26O (July 30, 2026), CMO 33F (August 31, 2026)

• 3M Company: Form 10-Q for the quarter ended September 30, 2026 (filed October 20, 2026)

• 3M Company: Form 8-K and Master Settlement Agreement with Exhibit 11 (Payment Schedule), filed November 3, 2026

• 3M Company: "3M Reaches Broad Resolution of AFFF Personal Injury Litigation," press release (November 3, 2026), and investor presentation (November 4, 2026)

• U.S. District Court (D.S.C.), MDL-2873: CMO 39 (Identification Order) and CMO 40, entered November 4, 2026

• U.S. District Court (D.S.C.), MDL-2873: joint motion to file Confidential Exhibit 12 under seal (November 3, 2026)

• DuPont de Nemours: Form 10-Q for the quarter ended September 30, 2026 (filed November 3, 2026)

• DuPont: North Carolina settlement release, filed with the SEC (September 2026)

Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.

Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.

Read our full disclaimer · Privacy Policy · Terms of Use